ChiCTR2300072017 版本V1.0 版本创建时间2023/05/31 16:10:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072017 

最近更新日期:

Date of Last Refreshed on:

2023-05-31 16:09:49 

注册时间:

Date of Registration:

2023-05-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于人工智能标准化病人的CBL教学模式构建与效果研究——以针对临床专科医师的大肠癌教学为例

Public title:

Construction and effect research of Artificial Intelligence-based Standardized patient CBL teaching model -- A case study of colorectal cancer teaching for clinical specialists

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于人工智能标准化病人的CBL教学模式构建与效果研究——以针对临床专科医师的大肠癌教学为例

Scientific title:

Construction and effect research of Artificial Intelligence-based Standardized patient CBL teaching model -- A case study of colorectal cancer teaching for clinical specialists

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴一波 

研究负责人:

史江漂 

Applicant:

Yibo Wu 

Study leader:

Jiangpiao Shi 

申请注册联系人电话:

Applicant telephone:

+86 188 1016 9630

研究负责人电话:

Study leader's
telephone:

+86 151 7575 7296

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bjmuwuyibo@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

1051114056@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中华人民共和国北京市海淀区学院路38号

研究负责人通讯地址:

中华人民共和国河北省保定市唐县向阳北街28号

Applicant address:

38 Xueyuan Road, Haidian District, Beijing, China

Study leader's address:

28 Xiangyang North Street, Tangxian County, Baoding City, Hebei Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学公共卫生学院

Applicant's institution:

School of Public Health, Peking University, Beijing 100191, China

研究负责人所在单位:

保定市第四中心医院

Affiliation of the Leader:

The Fourth Central Hospital of Baoding

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023032

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

保定市第四中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Fourth Central Hospital of Baoding

伦理委员会批准日期:

Date of approved by ethic committee:

2023-05-08 00:00:00

伦理委员会联系人:

赵文娟

Contact Name of the ethic committee:

Wenjuan Zhao

伦理委员会联系地址:

中华人民共和国河北省保定市唐县向阳北街28号

Contact Address of the ethic committee:

28 Xiangyang North Street, Tangxian County, Baoding City, Hebei Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 159 3075 8855

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

保定市第四中心医院

Primary sponsor:

The Fourth Central Hospital of Baoding

研究实施负责(组长)单位地址:

中华人民共和国河北省保定市唐县向阳北街28号

Primary sponsor's address:

28 Xiangyang North Street, Tangxian County, Baoding City, Hebei Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

河北省

市(区县):

Country:

China

Province:

Hebei Province

City:

单位(医院):

保定市第四中心医院

具体地址:

中华人民共和国河北省保定市唐县向阳北街28号

Institution
hospital:

The Fourth Central Hospital of Baoding

Address:

28 Xiangyang North Street, Tangxian County, Baoding City, Hebei Province, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

无  

Target disease:

N/A

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究基于人工智能标准化病人的CBL教学模式的应用效果  

Objectives of Study:

Explore the application effect of artificial intelligence-standardized patient CBL teaching mode

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄大于18岁 2.消化科学生 3.自愿参加该研究,填写知情同意书 4.能熟练使用智能手机

Inclusion criteria

1. Over 18 years old 2. Gastroenterology student 3. Volunteer for the study and fill in the informed consent form 4. Smart phone skills

排除标准:

1.项目开始前理论考试不合格者 2.正在参加其他课题者 3.参加过标准化病人的CBL教学的结直肠癌培训者

Exclusion criteria:

1. Failed to pass the theory test before the project began 2. Those who are taking part in other projects 3. Colorectal cancer trainers who have participated in standardized patient CBL teaching

研究实施时间:

Study execute time:

From 2023-03-01 00:00:00 To 2023-11-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-01 00:00:00 To 2023-08-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

28

Group:

control group

Sample size:

干预措施:

基于传统标准化病人的CBL教学

干预措施代码:

Intervention:

Case-based learning (CBL) teaching based on traditional standardized patient (SP)

Intervention code:

组别:

试验组

样本量:

28

Group:

experimental group

Sample size:

干预措施:

基于人工智能标准化病人的CBL教学

干预措施代码:

Intervention:

Case-based learning (CBL) teaching based on AI standardized patient (SP)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中华人民共和国

省(直辖市):

河北省 

市(区县):

 

Country:

China

Province:

Hebei Province

City:

单位(医院):

保定市第四中心医院 

单位级别:

三级 

Institution
hospital:

The Fourth Central Hospital of Baoding

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

理论考试成绩

指标类型:

主要指标

Outcome:

Theoretical test results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非技术操作性能力成绩

指标类型:

次要指标

Outcome:

Non-technical operational ability scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

学生满意度

指标类型:

次要指标

Outcome:

Students’ Satisfaction Degree

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

学生自我评价

指标类型:

次要指标

Outcome:

Students’ Self-evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 26 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化分组由史江漂利用Excel随机数(Rand)实施

Randomization Procedure (please state who generates the random number sequence and by what method):

Random grouping was implemented by Shi Jiang using Excel random number (Rand)

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

研究采用单盲原则,为避免资料收集员在收集资料时出现主观偏倚,本研究对资料收集员实施单盲,不告知资料收集员研究对象的分组情况和具体干预内容。

Blinding:

The study was single-blinded, and to avoid subjective bias in data collection by the data collectors, the study was single-blinded to the data collectors, who were not informed of the grouping of the study subjects or the specific interventions.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据收集:所有的研究结果,包括临床和试验室数据,都将记录在受试者的医疗记录和病例报告表(CRF)中。研究者负责确保CRF的所有部分都正确完成,并可以根据源数据进行验证。每个完成的CRF必须注明日期并签字。一份原始CRF的副本将被转移给试验首席研究员。最初的CRF将留给调查人员。 数据的存储和归档:研究者将将所有试验数据(受试者识别代码列表、源数据和研究者文件)和相关通信存档在研究数据库文件中。数据库所有来源数据和该研究的所有相关文件将在试验定稿后根据法律法规存档。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: All study results, including clinical and laboratory data, will be recorded in the subject's medical record and case report Form (CRF). The investigator is responsible for ensuring that all parts of the CRF are completed correctly and can be verified against source data. Each completed CRF must be dated and signed. A copy of the original CRF will be transferred to the lead investigator of the trial. The initial CRF will be left to investigators. Storage and archiving of data: The investigator will archive all trial data (subject identification code lists, source data, and investigator files) and related communications in a study database file. All source data of the database and all relevant documents of the study will be archived in accordance with laws and regulations after the trial is finalized.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-05-31 16:09:49